Oral aspartame and plasma phenylalanine: pharmacokinetic difference between rodents and man, and relevance to CNS effects of phenylalanine. Short note.
The ingestion of aspartame, a phenylalanine-containing dipeptide, raises plasma phenylalanine levels. These increments are much greater in humans than rats, because the rat hydroxylates phenylalanine five times faster than man. Accordingly, dose comparisons of aspartame (or phenylalanine) between humans and rats have usually been corrected by a factor of five. Recently, a correction factor of sixty has been proposed (Wurtman and Maher, 1987); the rationale is based on a novel calculation of competitive phenylalanine transport into brain. An analysis of the logic behind this postulation reveals there to be no basis for accepting the higher dose conversion of 60 between rat and man.
Fernstrom
J D
JD
Department of Psychiatry, University of Pittsburgh School of Medicine, Pennsylvania.
D000284:Administration, Oral; D000818:Animals; D001218:Aspartame / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001923:Brain Chemistry / Q000187:drug effects*; D004151:Dipeptides / Q000493:pharmacokinetics*; D006801:Humans; D010649:Phenylalanine / Q000097:blood* / Q000494:pharmacology; D051381:Rats; D013045:Species Specificity
D004151:Dipeptides; D010649:Phenylalanine; D001218:Aspartame